Atorvastatin API Market Segmentation:
Application (Hypercholesterolemia, Hypertriglyceridemia, Dyslipidemia)
hypercholesterolemia segment is set to dominate atorvastatin API market share of around 82.8% by the end of 2035. The growth is driven by extensive clinical research data on atorvastatin which has been proven to be effective in the management of LDL cholesterol and associated cardiovascular risk. For instance, in May 2024, AstraZeneca and CSPC Pharmaceutical Group Ltd (CSPC) signed an exclusive license agreement. The company's cardiovascular portfolio is further strengthened by this partnership, which aids in addressing the main risk factors for chronic cardiovascular disease. The rapidly increasing attention of healthcare professionals toward cholesterol management as an essential part of preventive measures for cardiovascular diseases further fuels the growing demand for atorvastatin APIs.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
